Stents
Promus Premier stent debuts in Japan
Medtech titan Boston Scientific (NYSE:BSX) has launched commercial efforts after landing Japanese regulatory approval for its Promus Premier drug-eluting stent.
Abbott closes 3 clinical trials for disappearing drug-eluting coronary stent
Over-stenting doc costs bosses $37M in patient complaints | MassDevice.com On Call
MASSDEVICE ON CALL — A years-old over-stenting dispute is coming to a head as the former owner of St. Joseph Medical Center in Maryland agreed to pay up to $37 million to resolve patient lawsuits.
Terumo inks deal for Arterial Remodeling’s bioresorbable stent
Arterial Remodeling Technologies said it inked a deal with Terumo Corp. (TYO:4543) for its bioresorbable drug-eluting coronary stent that includes an exclusive buyout option.
Boston Scientific lands E.U. approval for Rebel bare-metal stent
Medtech titan Boston Scientific (NYSE:BSX) won European regulatory approval for its Rebel bare-metal stent, a drug-free version of its Promus Premier device.
Svelte Medical raises another $5M
New Jersey-based Svelte Medical plans to accelerate regulatory efforts for its interventional cardiology products thanks to a new $5 million investment from West Health Investment Fund.
OrbusNeich launches Combo stent pivotal trial in bid for Japanese approval
OrbusNeich Medical said it launched a clinical trial in the U.S. and Japan for its Combo dual-therapy coronary stent as it gears up to apply for Shonin approval in Japan.
Medtronic, Abbott land 1st contracts with healthcare coalition SharedClarity
Boston Scientific lands expanded E.U. approval for WallFlex esophageal stent
Boston Scientific (NYSE:BSX) won expanded CE Mark approval for its WallFlex stent in the European Union, the company announced.
Tryton Medical lands added EU stent clearance
Tryton Medical said it won CE Mark approval in the European Union for its side-branch stent to treat left main coronary artery disease.
Durham, N.C.-based Tryton already has European clearance for the side branch stent, but only for treating bifurcated large-vessel lesions. The new approval makes the device the only stent cleared in Europe for the left main indication, according to a press release.